Abstract 23
Human Leukocyte Antigen (HLA) is an essential component of the immune system which stimulates 24 immune cells to provide protection and defense against cancer. More than thousands of HLA alleles 25 have been reported in the literature; but, only a specific set of HLA alleles expressed in an individual. 26 Recognition of cancer-associated mutations by the immune system depends on the presence of a 27 particular set of alleles, that elicit an immune response to fight against cancer. It indicates that the 28 occurrence of specific HLA alleles also affects the outcome of the cancer patients. In the current 29 study, prediction models have been developed using 415 skin cutaneous melanoma (SKCM) patients 30
for predicting the overall survival of patients from their HLA-alleles. It has been observed that, the 31 presence of certain superalleles in the patients, is responsible for improved overall survival which 32
were referred as favourable superalleles like HLA-B*55 (HR=0.15, 95% CI 0.034 to 0.67), HLA-33 A*01 (HR=0.5, 95% CI 0.3 to 0.8). In contrast, presence of certain superalleles in the patients is 34 responsible for their poor survival, those superalleles were referred as unfavourable superalleles such 35
as HLA-B*50 (HR=2.76, 95% CI 1.284 to 5.941), HLA-DRB1*12 (HR=3.44, 95% CI 1.64 to 7.2). 36 We developed prediction models using 14 HLA-superalleles and five clinical characteristics for 37 predicting high-risk SKCM patients and achieve HR=4.52 (95% CI 3.088-6.609) with p-value = 38 8.01E-15. Lastly, we provide a web-based service to community for predicting the risk in SKCM 39 patients (https://webs.iiitd.edu.in/raghava/skcmhrp/) 40 1
Introduction 41 HLA complex is highly polymorphic genetic region, located on chromosome 6, precisely 6p21. 3 42 region (1, 2) . Major histocompatibility complex (MHC) proteins encode more than 200 immune-43 related genes, from which, approximately 40 genes were associated with the development of 44 leukocyte antigens, i.e. Class I and Class II HLA genes (3). Out of which, class I genes encode 45 proteins which present antigens (intracellular peptides) to CD8 + T lymphocytes, while, class II genes 46 encode proteins which are present on antigen-presenting cells (APC) that regulate the proliferation 47
and initiation of CD4 + T cells(4,5). Furthermore, Class I HLA genes are of three types, i.e. A, B and 48 C, while class II HLA genes are of five types, which include DR, DP, DM, DQ, and DO. Class I 49 complex generally located on the nucleated cell surface, and Class II genes expressed on the specific 50 cells such as monocytes, macrophages, and dendritic cells also known as APCs, B lymphocytes and 51 activated T cells (2). 52
Human Leukocyte Antigen (HLA) molecules play a major/significant role in the induction and 53 regulation of immune responses. The role of HLA class I molecules has been implied in tumor 54 resistance to apoptosis (6) . Moreover, recent findings suggest that the altered expression of HLA 55 molecules was associated with metastatic progression and poor prognosis in tumor (7-9). The 56 modification of surface molecules, lack of co-stimulatory molecules, production of 57 immunosuppressive cytokines, and alterations in HLA molecules are some primary escape 58 mechanisms used by tumor cells to evade the immune response(10), which can directly affect the 59 survival of an individual. Figure 1 represents how the survival of the patients can get affected if 60
HLAs fails to recognize the tumor cells, which is ultimately responsible for the activation of the 61 immune system. Previous studies reveal that skin cutaneous melanoma has been reported to be the 62 most threatening and fatal form of skin cancer and scrutinized multi-omics signatures for the 63 progression of this malignancy (11-13). It has been shown that if melanoma is detected at an early 64 stage, the overall survival rate is 95%; but, once it is metastasized (lesion thickness >4mm); they are 65 tough to cure and the survival rate is reduced to less than 50% (14,15). Melanoma tumor cells escape 66 the immune checkpoints and proliferate at a higher rate than normal tissue cells (16). Further, it is 67 categorized as an immunogenic tumor as it's lesions have been found to have signatures of several 68
immune escape mechanisms such as downregulated expression of HLA molecules, secretion of 69 cytokines like IL10 and loss of tumor-specific antigens (17). 70 71
Figure 1: The identification of tumor cells by CD8 + cytotoxic T cells and CD4 + T helper cells via 72
HLA class I and II molecules, respectively. 73
For instance, the downregulation of class I antigens was associated with poor prognosis and 74 inadequate treatment in melanoma cases (18) (19) (20) . Moreover, recent studies demonstrate the 75 importance of HLA alleles in the prognosis of melanoma, such as the loss of heterozygosity of HLA 76 class I alleles (HLA-B*15:01) was shown to be related with poor survival outcome. Besides, HLA-C 77 alleles and HLA-B44 supertype were shown to enhance the overall survival (21-23), thereby 78 claiming that these molecules could be considered as prognostic markers for melanoma. Thus, it is 79 vital to analyse the role of class I and II antigens in the survival of melanoma patients. With the 80 knowledge of accurate HLA genotyping, one can design immunotherapy-based prognostic 81 biomarkers and personalized vaccines against cancer. 82
In the current study, we have made an attempt to understand the role of HLA (Class I and II) 
Study Design and Dataset Collection 94
The workflow of our study is illustrated in Figure 2 . The description of each step given below. 
Skin cutaneous melanoma patient's data 98
We have downloaded the SKCM controlled access dataset from GDC data portal. four-digit HLA typing was performed for each patient for the assignment of both Class I (-A, -B, -C) 112
and Class II (-DP, -DQ, -DR) HLA genes. Further, an allele is assigned to HLA-superallele on the 113 basis of common family alleles (Field F2), i.e. HLA-alleles were grouped to HLA-superalleles on the 114 basis of similar HLA-Gene (-A, -B, -C, -DPB1, -DQB1, -DRB1) and Field1 (F1) (which represents 115 the allele of a particular gene)(28), the complete representation is given in Figure 3 and 116 Supplementary Table S2 . 117 DPB1, -DQB1, -DRB1) and Field 1 (F1). F1 and F2 represent the allele group and specific HLA-120 protein respectively. 121
Categorization of HLA-Superalleles 122
Here, we categorized all HLA alleles into favourable and unfavourable groups based on the impact of 123 their presence on the survival of patients, i.e. whether the presence of superalleles either improve or 124 6 decrease the survival. Towards this, firstly, all patients were divided into two groups, i.e. patients 125 having a particular allele and the patients lacking it; subsequently, the mean survival of patients was 126 computed in each group. Further, an allele is assigned as survival favourable allele if the mean 127 survival of the patients having this allele is more than the mean survival of patients lacking this 128 allele. Similarly, an allele is assigned as an unfavourable allele, if the mean survival of the patients 129 containing this allele is lower than the mean survival of patients without this allele. It has been 130 observed that an individual allele is only present in the limited number of patients; thus, grouping 131 based on the occurrence of allele will be skewed. Therefore, eventually, we analyse the presence and 132 absence of HLA-superalleles in the patients and assigned them in favourable (SF) and unfavourable 133 (SU) superalleles groups. Notably, we considered only those superalleles, that must be present in 134 atleast ten samples before assigning it into any of these groups. Further, to study the overall impact 135
of the presence of SF and SU superalleles, we combine SF and SU superalleles and prepare a matrix; 136
where, we assign a score +1 if unfavourable and -1 if favourable superallele is present in an SKCM 137 patient, otherwise 0. Eventually, all the scores are cumulatively added to generate a single score 138 called "Risk Score". Subsequently, threshold-based methods have been developed using these 139 superalleles as features. Finally, we assign a patient on high-risk if the score is more than threshold of 140
Risk Score, otherwise low-risk. 141
Survival Analysis 142
In the current study, "Univariate" and "Multivariate" survival analysis is performed by using Cox 143
Proportional Hazard (Cox PH) models implementing 'survival' package in R (V.3.5.1). To 144 understand the impact of each variables like age, tumor stage, tumor status, sex, class I, II HLA-145 alleles, HLA-superalleles and Risk Score in the prognosis of SKCM patients, univariate analysis is 146 performed. Further, to determine the combined effect of multiple factors such as age, tumor stage, 147 tumor status, sex and class I, II HLA-superalleles, multivariate survival analysis is performed. The 148 log-rank test was used for the estimation of significant survival distributions between high-risk and 149 low-risk groups in terms of p-value. To demonstrate the performance of models graphically, high-150
risk and low-risk groups are represented by Kaplan-Meier plots (29). 151
2.6
Development of Prediction Models 152
Models based on machine learning techniques 153
In the current study, various machine learning techniques have been implemented to develop 154 regression models for the survival prediction in melanoma patients. These machine learning 155 techniques include Random Forest (RF) (30), Ridge, Lasso (31), and Decision tree (DT) (32). Most 156 of these techniques were implemented using python-library scikit-learn (33). To develop prediction 157 models, we used a wide range of features that include HLA-superalleles, clinical characteristics of 158 the patients like age, gender, stage, tumor status, Breslow depth, and combination of both. 159
Wrapper based feature selection method 160
Here, a recursive feature selection model was developed by adding one-by-one HLA-superalleles to 161 the clinical features based on the performance of each model. Then, survival time was predicted and 162 followed by computation of Hazard Ratio (HR) for each combination. Briefly, every time input 163 matrix was updated by adding a new column having HLA-superallele, which had the HR just higher 164 than that of the previous input matrix. We repeat this process until there is no further improvement in 165 HR. Finally, we are left with the matrix which attained the highest HR. Subsequently, this matrix was 166 used to build the final prediction model for estimation of OS time. 167
2.7
Evaluation of models 168
Five-fold cross-validation 169
In order to avoid the over optimisation in the training of models, we used standard five-fold cross-170 validation (34) . In brief, all instances are randomly divided into five sets; where, four sets are used 171
for the training and remaining fifth set for testing. This process is repeated five times so that each set 172 is used for testing atleast once. The final performance is calculated by averaging the performance on 173 all five sets. 174
Parameters for measuring performance 175
The major challenge in these types of studies is to use appropriate parameters for evaluating the 176 performance of models. In this study, we used standard parameter Hazard Ratio (HR) for measuring 177 the performance of the models. HR is a measure of the effect of an intervention on an outcome of 178 interest over time. Our regression models segregate patients into high-risk and low-risk groups by 179 taking median cut-off. In order to evaluate our model, we compute HR from the predicted group of 180 patients (high-risk or low-risk patients). Besides, we also measure the confidence interval (CI) with 181 HR and reported HR at 95% CI. In order to measure the significance of prediction, we also calculate 182 p-value by using log-rank test. These parameters were implemented previously in various similar 183 kind of studies (35,36). 184 3
Results 185
Distribution of HLA alleles 186
We have extracted 367 HLA alleles for 415 SKCM-patients from the HLA-genotyping of SKCM 187 cohort using xHLA software (37). Out of these 367 alleles, 237 belong to HLA-Class I genes (-A,-B,-188 C) and 130 alleles correspond to Class II genes (-DP, -DQ, -DR). We compute the frequency 189 distribution of different alleles in the patients. Due to heterogeneity in HLA-genes, all alleles are not 190 found in an individual, so the frequency of alleles vary in each patient (38). As shown in Figure 4A II, only 5 alleles are present in more than 100 patients as shown in Figure 4B and 4C, respectively. 197
The complete frequency distribution of class I and class II alleles in the SKCM-patients is given 198
in Supplementary Table S3 . 
Categorization of Superalleles into Favourable and Unfavourable Groups 208
In order to understand whether an allele is favourable for survival of the patient or not, we compute 209 difference in mean overall survival (MOS) of patients having and lacking a given allele (Table S3) both class of alleles as given in Supplementary Table S3 . These alleles can be used to predict risk of 217 survival, unfortunately, this statistics is biased as the number of patients having a particular allele is 218 very small for most of the alleles. This prompted us to create the superalleles from these alleles. 219
Therefore, HLA alleles were further assigned to superalleles on the basis of similarity in the HLA- Figure S1 . Distribution of superalleles which are present in at least ten patients is shown in Figure 5 . 225 The abundance of all remaining superalleles is given in Supplementary Table S4 . survival and frequency are represented in Table 1 . 240 
Risk Score 260
To further improve the performance of the prediction models, we developed a threshold-based 261 method using multiple superalleles as input features. In this case, we employed multiples variables 262 that include both favourable and unfavourable superalleles. Towards this, first, we assign -1 and +1 263
for each favourable and unfavourable superallele, respectively. Thereafter, all the scores are 264 cumulatively added to generate a single score called "Risk Score" for each patient. Further, to 265 understand how well Risk Score based on superalleles stratified risk-groups of melanoma patients, 266
survival analysis was performed using Risk Score as a input feature. For instance, if the threshold 267 value is >=2 then the patients significantly divided into high-risk and low-risk groups with more than 268 two-folds, i.e. HR 2.18 (95% CI 1.441 to 3.297) with p-value = 0.000223 as given in Table 2 . 269 Conclusively, we found that Risk Score thresholds act as a prognostic indicator for stratifying 270 melanoma patients into high-risk and low-risk groups, as shown in Table 2 . Additionally, Kaplan-271
Meier (KM) survival plots represent the segregation of high-risk and low-risk melanoma patients 272 based on different threshold values of Risk Score, with significant p-values as shown in Figure 6 . 273 Score) 282
Clinical Characteristics 283
In the past, the clinical features like age, gender, tumor stage, tumor status and Breslow depth have 284 been shown a significant effect on the skin cancer incidence and bias towards a particular group (39). 285
For instance, even in the current study, the male incidences are higher than of females in case of 286 melanoma as shown in Supplementary Table S1 . This prompted us to analyse the association 287 between these clinical features and the survival of the patients. Thus, we perform the univariate 288 survival analysis for the clinical features. This analysis indicates that the tumor status is one of the 289 major significant prognostic factors in the prediction of survival of melanoma. Here also, we used 290 threshold-based approach where we assign score +1 in case tumor is present in patient otherwise 291 zero. We predict patient high-risk if score is more than zero and obtained HR 8.293 (95% CI 4.688-292 14.67) with p-value less than 0.0001 ( Supplementary Table S6) 
Machine learning prediction models based on Wrapper method 329
It is important to have minimum number of features for avoiding over optimization and for the 330 practical implementation in the real life. Therefore, further wrapper method used to decrease number 331 of features recursively. In case of wrapper based recursive approach, one has to develop prediction 332 model to evaluate performance after adding/removing a feature. Here, we used recursive machine 333
learning method after addition of features approach. Finally, prediction models developed using five 334 clinical features (age, gender, tumor stage, tumor status, and Breslow depth) and various HLA-335 superalleles by implementing different machine learning techniques (Table 4 ). Similar to above 336 analysis, Lasso method based on five clinical features and 14 superalleles is the top performer with 337 HR of 4.52 and p-value 8.01E-15 as given in Table 4 . KM plot represents the stratification of high-338
risk and low-risk patients based on the estimated OS using Lasso recursive regression model as 339
shown in Figure 8 . 340 Supplementary Figure S2 , indicate that the presence of SU superalleles reduces the survival of 355 melanoma samples. SU patients' group is at approximately two times higher risk as compared to the 356 SF patients' group is indicated by HR = 2.44 (95% CI 1.68 to 3.5) with a p-value less than 3.02E-06, 357
shown in Table 5 . Both multivariate and univariate analysis reveals that age (>60), stage (III and IV), 358 Breslow depth (>3mm) and Risk Score (>0) are associated with the poor survival in melanoma 359 patients. 360 HLA-A*31, HLA-A*24 are significantly associated with poor outcome of melanoma cohort in terms 368 of their survival time as given in Supplementary (Table S7 , S8 and Figure S3 , S4). 369
Web Server for risk prediction in SKCM patients: SKCMhrp 370
To serve the scientific community, we developed a web server, "SKCMhrp" 371 https://webs.iiitd.edu.in/raghava/skcmhrp/. SKCMhrp is designed for the risk prediction using 372 clinical features and HLA-superalleles. It has two modules; one is based on clinical features and 373 second is based on superalleles. In the current study, multivariate analysis reveals SF and SU HLA-superalleles as the independent 419 prognostic indicators. For instance, the presence of HLA-Class I superalleles include HLA-B*55 420 (HR=0.15, p-value=0.013) and HLA-A*01(HR=0.54, p-value=0.011)) are significantly associated 421 with good outcome ( Supplementary Table S7 , Figure S4 ). On the other hand, superalleles such as 422 HLA-B*50 (HR-3.35, p-value=0.02), HLA-DRB1*12 (HR=3.44, p-value=0.028), HLA-DRB1*16 423 (HR=2.18, p-value=0.04), HLA-B*13 (HR=2.49, p-value=0.04), HLA-DPB1*06 (HR=3.15, p-424 value=0.006), HLA-A*31 (HR=2.09, p-value=0.01) and, HLA-A*24 (HR=1.76, p-value=0.006) 425 associated with the poor survival outcome in SKCM-cohort ( Supplementary Table S8 , Figure S5 ). 426
Eventually, the multivariate analysis revealed the Risk score, tumor status, tumor stage, Breslow 427 depth and age as major independent prognostic factors for melanoma patients. Besides, the low 428 expression (with mean cut-off) of HLA (-A, -B, -C, -DPB1, -DQB1, -DRB1) genes, consequently 429 decreases the OS rate of melanoma cohort shown in Supplementary Table S9 . Furthermore, various 430 prediction models developed for the estimation of survival time of patients based on clinical 431 characteristics, HLA-superalleles genotypes, and their various combinations implementing different 432 machine learning techniques, i.e. Lasso, Random forest, DT and Ridge regression models. 433
Subsequently, the predicted OS from these machine learning algorithms further employed for the 434 stratification of high-risk and low-risk survival groups. Although, the prediction based on five 435 clinical factors attained consistent performance, i.e. HR=3.17; but, stage and tumor status are two 436 important factors which are mostly not available as their determination is a difficult task. Therefore, 437
we have also developed prediction models after exclusion of these two factors. The performance of 438 our ML models substantially decreased to HR 2.40. Further, prediction models developed employing 439 important clinical factors with HLA-superalleles and removing tumor stage and tumor status as well. 440
Results indicate that the performance of models based on HLA-superalleles and conveniently 441 available clinical factors like age, gender and Breslow depth considerably improved from HR (2.40 442 to 3.11). Lasso and RF recursive regression models are among the top performers to predict survival 443 of melanoma samples. Particularly, predicted OS obtained from Lasso recursive model, based on 444 clinical characteristics and nine-superalleles significantly (p-value<0.001) stratified the high-risk and 445 low-risk survival groups of the melanoma patients with HR=4.52. Although, RF-based models 446 performed reasonably well in the estimation of OS, but, stratified survival risk groups with lower 447 performance than that of Lasso models, i.e. HR=3.53 only. 448
Conclusion 449
Taken together, our findings exhibit that the occurrence of HLA-Class I, II alleles genotype influence 450 the overall survival of SKCM patients both in favourable and unfavourable directions. Eventually, 451 survival analysis and recursive machine learning regression models revealed the prognostic potential 452 of important 14 superalleles and five clinical factors in the stratification of high-risk and low-risk 453 survival groups and the estimation of overall survival time, respectively. Further, these HLA-based 454 signatures could be considered to design personalized vaccine in several clinical cohorts. For the 455 clinical utility, this further needs to confirm by exploring the role of these superalleles in other 456 cohorts. Finally, to provide service to scientific community for prediction of high-risk patients based 457 on their clinical features and 14 HLA-superalleles, we designated webserver "SKCMhrp". 458
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